a balanced article which also points out discontinuations and variable benefits. Not sure I'm more confident having read this although given no other treatment is available a case by case use would seem reasonable given safety is fine. This would then mean fda might lean towards approval. - I hope for all concerned.
a balanced article which also points out discontinuations and...
-
- There are more pages in this discussion • 217 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.03 |
Change
-0.695(3.35%) |
Mkt cap ! $2.570B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $2.218M | 110.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 30 | $20.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.04 | 211 | 2 |
View Market Depth
| Last trade - 12.31pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |